

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 June 2001 (21.06.2001)

PCT

(10) International Publication Number
WO 01/43764 A2

(51) International Patent Classification⁷: **A61K 38/00**

(21) International Application Number: PCT/US00/34000

(22) International Filing Date:
15 December 2000 (15.12.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/466,559 17 December 1999 (17.12.1999) US
09/707,395 7 November 2000 (07.11.2000) US

(71) Applicant and
(72) Inventor: FALLON, Joan, M. [US/US]; 830 Pelhamdale
Avenue, New Rochelle, NY 10801 (US).

(81) Designated States (*national*): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— Without international search report and to be republished upon receipt of that report.

(74) Agents: DEROSA, Frank, V. et al.; F. Chau & Associates, LLP, 1900 Hempstead Turnpike, Suite 501, East Meadow, NY 11554 (US).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHODS FOR TREATING PERVASIVE DEVELOPMENT DISORDERS

(57) Abstract: A method of utilizing the chymotrypsin level of an individual as a measure of the success of secretin, other neuropeptides, and peptides or digestive enzyme administration to such individuals, and in particular, as a prognosticative of potential secretin, other neuropeptides, peptides, and digestive enzyme administration for persons having ADD, ADHD, Autism and other PDD related disorders. In one aspect, a method for determining the efficacy of secretin, other neuropeptides, peptides, or digestive enzymes for the treatment of an individual diagnosed with a pervasive development disorder (PDD) comprises obtaining a sample of feces from an individual, determining a quantitative level of chymotrypsin present in the sample, and correlating the quantitative level of chymotrypsin determined to be present in the sample with the PDD to determine the efficacy of treating the individual with secretin, other neuropeptides, peptides, or digestive enzyme administration. In another aspect, a therapeutic method for treating an individual diagnosed with a PDD pervasive development disorder comprises determining the efficiency of secretin, other neuropeptides, peptides, and digestive enzymes administration for the treatment of the individual based on a measure of the individual's chymotrypsin level, and administering secretin, other neuropeptides, peptides, or digestive enzymes to the individual based on the determination of the measure of the individual's chymotrypsin level.

WO 01/43764 A2

METHODS FOR TREATING PERVASIVE DEVELOPMENT DISORDERS

BACKGROUND

1. Technical Field:

5 The present invention relates generally to a method for treating individuals diagnosed with a form of PDD (pervasive development disorder) and other disorders such as ADD (attention deficit disorder) and ADHD (attention deficit hyperactivity disorder). More specifically, the present invention is directed to therapeutic method for treating individuals with such disorders by administering secretin, other neuropeptides, peptides, and/or digestive
10 enzymes, as well as a prognosticative method for determining the potential effectiveness of the administration of secretin, other neuropeptides, peptides, and/or digestive enzymes for the treatment of such disorders.

2. Description of Related Art:

 PDDs are a class of disorders defined by both American and International diagnostic
15 systems (i.e., the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) and World Health Organization: International Classification of Diseases, Tenth revision (ICD-10)). The spectrum of PDDs include disorders such as Autism, Aspergers, ADD, and ADHD. PDDs are typically characterized by multiple distortions in the development of basic psychological functions that are involved in the development of social skills and language,
20 such as attention, perception reality testing and motor movement. In addition, many children diagnosed with Autism, for example, suffer from primary diffuse gastrointestinal problems such as protracted diarrhea and constipation. Although PDDs are currently of unknown etiology, many conventional methods, such as dietary alteration, behavioral modification, and medication, have been utilized for treating individuals suffering from PDD related disorders.
25 Unfortunately, PDD related disorders have no known treatment beyond that which is symptomatic, and these conventional methods have proven unsuccessful in allowing such children and adults to become symptom, or disorder free.

 A child which displays signs of developmentally inappropriate inattention, impulsivity and hyperactivity is typically diagnosed as having ADD and/or ADHD. With these
30 disorders, there can be marked disturbances of organization, distractibility, impulsivity,

restlessness, and other disturbances of language and/or social behavior. A combination of psychiatric care and medicine is typically used for treating children with ADD and ADHD.

It was recently discovered that the administration of secretin, a gastrointestinal peptide hormone, to children diagnosed with Autism resulted in ameliorating the symptoms

5 associated with Autism. This finding was published in the article by Horvath et al., entitled *Improved Social and Language Skills After Secretin Administration In Patients with Autistic Spectrum Disorders*, Journal of the Association for Academic Minority Physician Vol.9 No.1,

pp. 9-15, January, 1998. The secretin administration, as described in Horvath, was performed as a diagnostic procedure, i.e., to stimulate pancreatobiliary secretion during an

10 upper gastrointestinal endoscopy, rather than as a therapeutic procedure. Although the specific mechanism by which the secretin improved the autistic-related symptoms was not specifically identified, Horvath postulated that secretin may have had a direct or indirect effect on the central nervous system. What is important, however, is that this was the first time that gastrointestinal problems of autistic children were linked to a possible etiology in

15 Autism.

Accordingly, in view of such findings, a method for determining whether an individual suffering from a disorder in the PDD spectrum will benefit from the administration of secretin, other neuropeptides, peptides and/or digestive enzymes, as well as a therapeutic

method for treating such individuals with the administration of secretin, other neuropeptides, 20 peptides and/or digestive enzymes, are highly desired.

SUMMARY OF THE INVENTION

The present invention is directed to a method of analyzing the chymotrypsin level of an individual to determine the potential benefit of the administration of secretin, other neuropeptides, peptides and/or digestive enzyme administration to such individual, and in 25 particular, as a prognosticative of potential secretin, other neuropeptides, peptides, and/or digestive enzyme administration for individuals diagnosed as having ADD, ADHD, Autism and other PDD related disorders.

In one aspect, a method for determining the efficacy of secretin, other neuropeptides, peptides, or digestive enzymes for the treatment of an individual diagnosed with a pervasive 30 developmental disorder (PDD) comprises obtaining a sample of feces from an individual,

determining a quantitative level of chymotrypsin present in the sample, and correlating the quantitative level of chymotrypsin determined to be present in the sample with the PDD to determine the efficacy of treating the individual with secretin, other neuropeptides, peptides, or digestive enzyme administration.

5 In another aspect, a therapeutic method for treating an individual diagnosed with a PDD pervasive developmental disorder comprises determining the efficacy of the administration of secretin, other neuropeptides, peptides, and digestive enzyme for the treatment of the individual based on a measure of the individual's chymotrypsin level, and administering secretin, other neuropeptides, peptides, or digestive enzymes to the individual
10 based on the determination of the measure of the individual's chymotrypsin level.

 The present invention involves determining the presence of abnormal protein digestion of individuals, especially children, by measuring the chymotrypsin levels so as to determine if the individual is likely to benefit from the administration of secretin, digestive enzymes, peptides and/or neuropeptides. Although there have been methods to test fecal
15 samples for indications of cystic fibrosis and pancreatic diseases in infants, none of the known methods have tested fecal samples in determining the benefits of administering secretin, other neuropeptides, peptides and/or digestive enzymes to individuals suffering from a PDD. Indeed, in so far as an individual's fecal chymotrypsin level is a broad measure of protein and fat digestion, such levels can be applied to all those who may benefit from
20 improvements in this mode of digestion. Furthermore, as low measures of fecal chymotrypsin expresses an abnormality of protein digestion, it is postulated that an improvement of protein digestion to promote normal growth and development of an individual suffering from a PDD by the administration of secretin, other neuropeptides, peptides and/or digestive enzymes, can ameliorate the symptomatology of PDDs.

25 Accordingly, in another aspect of the present invention, a therapeutic method is provided for treating an individual diagnosed with a PDD including but not limited to Autism, Aspergers, ADD and ADHD, comprising the steps of:

 determining the effectiveness of secretin administration for the treatment of the individual based on a measure of the individual's chymotrypsin level; and
30 administering secretin therapy to the individual based on the determination of the measure of the individuals chymotrypsin level.

In yet another aspect, the therapeutic method involves administering a fecal chymotrypsin test to measure an individual's fecal chymotrypsin level. Preferably, an enzymatic spectrophotometry method is used for measuring the fecal chymotrypsin level of the individual. Upon determining that an individual has an abnormal level of chymotrypsin, the individual is preferably administered 1U/kg of body weight of porcine or human secretin by means of an intravenous push method. This method can be described as the administration of an IV push of saline solution and secretin to equal 1U/kg of body weight. The individual then receives 1 unit test dose (absolute). A period of one minute is allowed to pass to determine if the individual has any allergic reactions to the secretin. After one minute has elapsed, if no urticarial reaction or any other allergic reaction has occurred, the remainder of the dose is administered. Subsequent fecal chymotrypsin samples are then gathered at one week intervals post administration to determine any changes in the chymotrypsin levels.

These and other aspects, features and advantages of the present invention will be described and become apparent from the following detailed description of preferred embodiments, which is to be read in connection with the accompanying drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 illustrates the overall net change in results of a CARS test (Childhood Autism Rating Scale) depicting behavior of 16 autistic children pre-secretin and post-secretin administration, where the solid lines indicate pre-secretin scores and the dotted lines indicate post-secretin scores;

Fig. 2 illustrates percentage change from pre-secretin to post-secretin administration in the average scores of the respective components of the CARS test of Fig. 1;

Fig. 3 illustrates the change in CARS scores for the sub-class Visual response from pre-secretin administration to three weeks post-secretin administration, where the solid lines indicate pre-secretin scores and the dotted lines indicate post-secretin scores;

Fig. 4 illustrates the change in CARS scores for the sub-class Verbal Skills from pre-secretin administration to three weeks post-secretin administration, where the solid lines indicate pre-secretin scores and the dotted lines indicate post-secretin scores;

Fig. 5 illustrates the change in CARS scores for the sub-class Touch/Taste/Smell from pre-secretin administration to three weeks post-secretin administration, where the solid lines indicate pre-secretin scores and the dotted lines indicate post-secretin scores;

Fig. 6 illustrates the change in CARS scores for the sub-class Object Use from pre-secretin administration to three weeks post-secretin administration, where the solid lines indicate pre-secretin scores and the dotted lines indicate post-secretin scores;

Fig. 7 illustrates the change in CARS scores for the sub-class Listening from pre-secretin administration to three weeks post-secretin administration, where the solid lines indicate pre-secretin scores and the dotted lines indicate post-secretin scores;

Fig. 8 illustrates the change in CARS scores for the sub-class Imitation from pre-secretin administration to three weeks post-secretin administration, where the solid lines indicate pre-secretin scores and the dotted lines indicate post-secretin scores;

Fig. 9 illustrates the change in CARS scores for the sub-class Body Use from pre-secretin administration to three weeks post-secretin administration, where the solid lines indicate pre-secretin scores and the dotted lines indicate post-secretin scores;

Fig. 10 illustrates the change in CARS scores for the sub-class Adaptation to Change from pre-secretin administration to three weeks post-secretin administration, where the solid lines indicate pre-secretin scores and the dotted lines indicate post-secretin scores;

Fig. 11 illustrates the change in CARS scores for the sub-class Activity Level from pre-secretin administration to three weeks post-secretin administration, where the solid lines indicate pre-secretin scores and the dotted lines indicate post-secretin scores;

Fig. 12 illustrates the change in CARS scores for the sub-class General Impression from pre-secretin administration to three weeks post-secretin administration, where the solid lines indicate pre-secretin scores and the dotted lines indicate post-secretin scores;

Fig. 13 illustrates the measured fecal chymotrypsin levels of 16 autistic children pre-secretin administration;

Fig. 14 illustrates the measured fecal chymotrypsin levels of the 16 autistic children approximately one week post-secretin administration;

Fig. 15 illustrates the measured fecal chymotrypsin levels of 28 ADD children;

Fig. 16 illustrates the measured fecal chymotrypsin levels of 34 ADHD children; and

Fig. 17 illustrates Ritalin levels administered before and after secretin administration in five of the ADHD children in Fig. 16, where the shaded bars indicate pre-secretin Ritalin levels and the non-shaded bars indicate post-secretin Ritalin levels.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

5 The present invention is directed to a method of analyzing chymotrypsin levels in persons, especially children, as a measure of the success of administering secretin, other neuropeptides, peptides and/or digestive enzymes for the therapeutic treatment of ADD, ADHD, Autism, Aspergers and other PDD related disorders. The use of secretin for the treatment of Autism is presently in the investigational stages. When the positive affects of
10 the neuropeptide secretin on childhood autism were first discovered and published, research was conducted by the present inventor to formulate a process that would enable one to definitively determine if individuals, especially children, having a PDD could be tested prior to the administration of secretin for its possible efficacy for treating PDD. Tests were performed to measure the fecal chymotrypsin levels (referred to herein as Fecal Chymotrypsin
15 Test) in children who span the entire PDD spectrum and whose symptomatology place them in this DSM IV category. As demonstrated below, such tests revealed that a majority of the children diagnosed with autism, ADD and ADHD, for example, had abnormal chymotrypsin levels. It is believed that such abnormal levels of chymotrypsin have not heretofore been identified in the PDD population of children and adults.

20 It is postulated that the abnormal levels of chymotrypsin are due to the inability of the pancreas to release bicarbonate ions, due to the lack of secretin mechanization in the small intestines. The small intestine has a pH in the range of 1.0-1.5 when the bolus of food enters the small intestines. Normally, plasma concentrations of secretin increase when the duodenal pH is below 4.5, and typically doubles during the postprandial period. The s cells in the
25 proximal portion of the small intestines release secretin in response to this low pH. The secretin is then released into the bloodstream and ultimately reaches the pancreas. In response, the pancreas releases bicarbonate ions, water and electrolytes into the small intestines thus neutralizing the pH by bringing it from a 1.0-1.5 to approximately 6.5.

 Following this, the pancreas secretes the enzyme trypsin in an inactive form
30 trypsinogen. The trypsinogen is converted to trypsin in the small intestines. In an

environment where the pH is 6.5 or greater, the trypsin catalyzes the formation of chymotrypsinogen to chymotrypsin. These enzymes are essential for the digestion of protein. In the absence of protein digestion, the amino acids necessary for the growth and development of individuals are absent. Therefore, based on tests performed by the present
5 inventor, it is postulated that the increase of protein digestion of an individual suffering from PDD can lead to the improvement of such disorders. Accordingly, since secretin is responsible for aiding in the protein digestion process, it has been determined that the presence of abnormal protein digestion in individuals, especially children, is indicative of which individuals are likely to benefit from the administration of secretin.

10 Indeed, in accordance with the present invention, experimental results have shown that the potential benefit of administering secretin, other neuropeptides, peptides and/or digestive enzymes to individuals diagnosed with developmental disorders falling within the entire spectrum of PDD may be predetermined by analyzing the measured fecal chymotrypsin levels of such individuals. More specifically, as illustrated below, it has been determined
15 that sub-normal to abnormal levels of fecal chymotrypsin in children/adults with PDD symptoms will benefit from the administration of secretin, other neuropeptides, peptides and/or digestive enzymes. In addition, experimental tests by the present inventor have revealed that the administration of secretin, other neuropeptides, peptides and/or digestive enzymes to others beyond those of who are autistic, especially those diagnosed with ADD
20 and ADHD will benefit from the administration of secretin, other neuropeptides, peptides and/or digestive enzymes.

The following experiments describe exemplary diagnosis and treatment procedures in accordance with the invention. It is to be understood that these experiments and corresponding results are set forth by way of illustration only, and nothing therein shall be
25 construed as a limitation on the overall scope of the invention.

I. EXPERIMENT 1

In this experiment, 16 children diagnosed as having autism were administered the following Fecal Chymotrypsin Test in accordance with an embodiment of the invention. First, approximately 2 grams of stool were collected from each child and placed in a sterile
30 container (although it is to be understood that any quantity of stool may be collected, as 2

grams of stool is not a required amount). Each stool sample was then analyzed using, e.g., an enzymatic photospectrometry analysis as is known by those skilled in the art, to determine the level of fecal chymotrypsin in the stool. Although the enzymatic photospectrophotometry process is preferred, any suitable conventional method may be used for measuring the fecal chymotrypsin levels. The measured chymotrypsin levels of the 16 autistic children are illustrated in Fig. 13.

After determining the chymotrypsin levels of the stools, each of these levels were compared with threshold chymotrypsin levels to determine if the child was likely to benefit from secretin administration. By way of example, with the fecal chymotrypsin tests of the stool samples being performed at 30°C, normal levels of chymotrypsin are deemed to lie above 8.4 U/gram, whereas pathologically abnormal levels are deemed to lie below 4.2 U/gram. In addition, chymotrypsin levels between 8.4 U/gram and 4.2 U/gram are considered equivocal, and further testing of the individual's fecal chymotrypsin levels over a period of time should be performed. It is to be noted that as shown in Fig. 13, all of the 16 autistic children that were tested had abnormal levels of fecal chymotrypsin pre-secretin administration.

Another stool sample was then collected from each child two days after the first test and analyzed to determine the chymotrypsin levels. This second test is preferably performed to obtain additional chymotrypsin measurements to make a more accurate determination.

Those children having abnormal levels of chymotrypsin in their stools are considered candidates for secretin administration. Other factors that may be considered in determining which children are potential candidates for secretin administration aside from the fecal chymotrypsin levels include a previously diagnosed history of autism, a history of gastrointestinal (GI) dysfunction, including any history of protracted diarrhea or constipation lasting for a weeks or months, as well as a self-limiting diet consisting primarily of carbohydrates.

Upon determining that a given child was likely to benefit from secretin administration based on the results of the fecal chymotrypsin test, the child was administered a CARS (Childhood Autism Rating Scale) test prior to being scheduled for secretin infusion.

For each of the 16 autistic children tested, a preferred secretin infusion process according to the present invention was performed involving the administering of 1 U/kg of

body weight of Secretin-Ferring for a period of nine months at intervals of approximately 6 weeks. In addition, another CARS test was administered to each of the 16 autistic children 3 weeks post secretin administration to determine if their autism had changed post infusion.

5 A preferred secretin infusion process includes the initial step of prepping an arm of the candidate child with an IV injection of saline. A test dose of 1U of Secretin-Ferring is then administered to the child. Approximately one minute after infusion, the child is examined for signs of allergic reaction including rash, increased heart rate, and increase of blood pressure. If the child does not display any signs of allergic reaction, the remaining units of Secretin-Ferring is administered to the child in the manner of an IV push, which is
10 then followed by a saline flush. Subsequently, each child receives a 1U/kg of body weight infusion of Secretin-Ferring approximately every 6 weeks for 9 months. It is to be understood that any commercially available form of secretin may be used.

Results of Experiment 1

The results of Experiment 1 are illustrated in Figures 1-14. For instance,
15 approximately one week after the first secretin infusion, the fecal chymotrypsin level of each of the 16 autistic children was measured again. The results of this test are illustrated in Fig. 14. As shown, the chymotrypsin level of each of the 16 autistic children test increased post-secretin administration (as compared with the levels shown in Fig. 13).

In addition, Figure 1 illustrates the pre-secretin CARS test results (solid line) and the
20 post-secretin CARS test results (dotted line) for each of the 16 autistic children tested approximately 3 weeks after the first secretin administration. Most notably, Fig. 1 illustrates an overall decrease in the CARS scores indicating improvements in the PDD/autistic symptoms of the children. In particular, Figure 2 illustrates respective percentage decreases in components of CARS scores, wherein the numbers represent percentage change in the
25 average of the scores in each component of the CARS test post-secretin administration. In particular, Figs. 3-12 illustrate the improved scores of each of the 16 autistic children for the individual components of the CARS scores. As shown, the component scores demonstrated improvement except for the fear component which increased 3 weeks post infusion.

II. EXPERIMENT 2

In this experiment, 37 autistic children with abnormal fecal chymotrypsin levels were administered secretin over the course of 6 months using the secretin infusion process described above. Their fecal chymotrypsin (FC) levels were measured weekly using the fecal chymotrypsin test described above.

Results of Experiment 2

Out of the 37 autistic children tested, the fecal chymotrypsin levels of 34 children had returned to normal after 6 months, the fecal chymotrypsin levels of 2 children moved to equivocal, and the fecal chymotrypsin level of 1 child remained abnormal. These results of this experiment are listed in the following Table 1.

Table 1

Autistic Children Tested	Pre-Secretin Administration	6 Months Post-Secretin Administration
# Autistic Children w/ Abnormal FC levels	37	1
# Autistic Children w/ Equivocal FC levels	0	2
# Autistic Children w/ normal FC levels	0	34

III. EXPERIMENT 3

In this experiment, the fecal chymotrypsin levels of 28 children diagnosed with ADD were obtained using the fecal chymotrypsin test described above in Experiment 1. Figure 15 illustrates the measured fecal chymotrypsin levels of these 28 children. It is to be noted that, as shown in Fig. 15, all of the 28 ADD children were found to have sub-normal fecal chymotrypsin levels since all of the values fell below 8.4 U/g. More specifically, 8 out of 28 children were determined to have an equivocal fecal chymotrypsin level and 20 out of the 28 children were determined to have a pathologic level of fecal chymotrypsin. As noted above, a chymotrypsin level of 8.4 U/g is considered a reference value for normal levels of chymotrypsin.

Of these 28 children who were diagnosed with ADD and abnormal fecal chymotrypsin levels, 10 were administered digestive enzymes comprising amylase, proteases, lipases, sucrase, maltase, and other digestive enzymes. These digestive enzymes were administered

one tablet at each mealtime (i.e., three times a day), adjusted for the age and weight of the child. More specifically, for the ADD children ages 1-6, a quantity of digestive enzymes of approximately 4,000-8,000 U.S.P. Units/tablet comprising lipase, amylase and protease were administered. For the ADD children of ages 7-12, a quantity of digestive enzymes of approximately 8,000-12,000 U.S.P. Units/tablet comprising lipase, amylase and protease were administered. Other digestive enzymes that were administered in smaller quantities included cellulase, sucrase and maltase. These digestive enzymes were administered over a period of 6 months.

Results of Experiment 3

At the time of this experiment, 4 out of the 10 children who were administered the digestive enzymes were taking Ritalin. As is known in the art, Ritalin is a stimulant medication used to treat children and adults with ADD and ADHD. More specifically, it is used to treat hyperactivity and attention problems. As a result of the administration of the digestive enzymes, all of the 4 children who had been taking Ritalin were able to completely stop taking the Ritalin. In addition, significant improvements in the behavior of the other 6 children were noted. These results are shown in the following Table 2:

Table 2

# ADD Children w/ Sub-normal FC levels	28
# of the 28 ADD Children With Abnormal FC levels That Were Administered Digestive Enzymes	10
# of the 10 ADD Children That Were Administered Digestive Enzymes Who Were Taking Ritalin	4
# ADD Children Requiring Ritalin Administration 6 months Post Administration of Digestive Enzymes	0

IV. EXPERIMENT 4

In this experiment, the fecal chymotrypsin levels of 34 children diagnosed with ADHD were obtained using the fecal chymotrypsin test described above in Experiment 1, the levels of which are illustrated in Fig. 16. As shown, 32 children out of 34 children tested were determined to have sub-normal fecal chymotrypsin levels. It is to be further noted that 24 of the 34 children were found to have pathologic levels of fecal chymotrypsin.

To determine the effect of secretin administration on ADHD children, 5 of the 24 children having a pathologic fecal chymotrypsin level were administered secretin using the secretin infusion process described above.

Results of Experiment 4

5 The results of this experiment are set forth in Fig. 17, which illustrates the required levels of Ritalin (in mg) of the 5 children tested both pre-secretin administration (as indicated by the shaded bars) and 6 months post-secretin administration (as indicated by the non-shaded bars). It is to be appreciated that as shown in Fig. 17, each of the 5 children who were administered secretin demonstrated significant changes post-secretin administration with
10 respect to the level of Ritalin (mg) that each child needed to remain at the same functional level as their functional level prior to secretin administration.

V. EXPERIMENT 5

 In this experiment, to determine the effect of the administration of digestive enzymes to ADHD children, 9 children of the 34 children diagnosed with ADHD (in
15 experiment 4 described above) whose fecal chymotrypsin levels were determined to be pathologic were administered digestive enzymes. Such digestive enzymes included amylase, lipase, proteases, sucrases, maltase, and other digestive enzymes. Each child was administered 1 tablet of digestive enzymes at each mealtime (i.e., three times a day), adjusted for age and weight of the child. More specifically, for the ADHD children ages 1-6, a
20 quantity of digestive enzymes of approximately 4,000-8,000 U.S.P. Units/tablet comprising lipase, amylase and protease were administered. For the ADHD children of ages 7-12, a quantity of digestive enzymes of approximately 8,000-12,000 U.S.P. Units/tablet comprising lipase, amylase and protease were administered. Other digestive enzymes that were administered in smaller quantities included cellulase, sucrase and maltase. The digestive
25 enzymes were administered over a 6 month period.

Results of Experiment 5

 It is to be appreciated that as a result of the administration of digestive enzymes over the 6 month period, all 9 children were able to reduce their required Ritalin levels. Most

notably, 2 of the 9 children were able to stop taking Ritalin after 6 months of digestive enzyme administration. The results of experiment 5 are illustrated in the following Table 3:

Table 3

# ADHD Children w/ Abnormal FC levels Who Were Administered Digestive Enzymes	9
# Of The 9 ADHD Children Whose Ritalin Levels Were Reduced 6 months Post-Digestive Enzyme Administration	9
# Of The 9 ADHD Children Who Stopped Taking Ritalin 6 Months Post-Digestive Enzyme Administration	2

VI. EXPERIMENT 6

The following experiment was performed to determine the effect of the administration of digestive enzymes to Autistic children. In this experiment, the fecal chymotrypsin levels of 17 autistic children of varying ages were measured (pre-digestive enzyme administration) using the method described above in Experiment 1. In addition, the fecal chymotrypsin levels of these 17 children were measured 6 months post digestive enzyme administration after receiving digestive enzyme therapy as described below. The following table demonstrates the measured fecal chymotrypsin levels of these 17 children:

Table 4

Patient	Age	Pre-DE Administration Fecal Chymotrypsin Levels	6-Months Post-DE Administration Fecal Chymotrypsin Levels
1	2.5	3.3	7.1
2	7	1.5	3.8
3	9	4.0	7.8
4	3.5	2.0	10.2
5	5	3.3	8.0
6	4	1.0	6.8
7	8	1.6	10.2
8	6	4.0	12.2
9	7	6.8	14.9
10	3	2.8	6.2

11	5	3.4	not available
12	3	2.0	4.0
13	2	4.0	4.6
14	11	3.3	5.0
15	9	2.2	9.2
16	8	1.4	12.0
17	7	3.8	6.0

As illustrated, each of the 17 autistic children were found to have either su-normal or pathologic fecal chymotrypsin levels. In particular, the fecal chymotrypsin level of patient #9 was found to be sub-normal as it fell below 8.4 U/g and the fecal chymotrypsin levels of the remaining 16 children were found to be pathologic since the levels fell below 4.2 U/g.

Each of the 17 autistic children were administered digestive/pancreatic enzymes comprising amylases, proteases, lipases, sucrases, maltases, and other digestive/pancreatic enzymes including trypsin and chymotrypsin. The digestive enzymes were administered on a daily basis at each mealtime, preferably 3-6 times per day. The quantity of digestive enzymes were adjusted for the weight and ages of the child. For instance, depending on the weight and age of the child, a preferred quantity of lipases ranges from 4,000 - 20,000 U.S.P., a preferred quantity of proteases ranges from 10,000 - 50,000 U.S.P., a preferred quantity of amylases ranges from 10,000 - 60,000 U.S.P., a preferred quantity of pancreatin (pancreatic extract) ranges from 2,000 - 6,000 U.S.P., a preferred quantity of chymotrypsin ranges from 2-5 mg and a preferred quantity of trypsin ranges from 60 - 100 mg. In addition, any combination of two or more types of any of the above digestive enzymes may be administered.

Results of Experiment 6

As illustrated in Table 4, the measured fecal chymotrypsin levels of at least 16 of the 17 autistic children were found to increase 6 months post-digestive enzyme administration. Most notably, the fecal chymotrypsin levels of 5 children (patients # 4, 7, 8, 15, and 16) that were initially found to be pathologic had increased to the normal range 6 months post-digestive enzyme administration.

Furthermore, a notable decrease in autistic symptomatology of each of the 17 autistic children was observed as a result of digestive/pancreatic enzyme administration. These observations are outlined in the following tables.

Table 5 outlines the responses that were reported after administration of digestive enzymes to the autistic children in the range of ages 2-4 (i.e., 6 of the 17 children listed in Table 4). Each numeric entry in Table 5 indicates the number of children (of the 6 children ages 2-4) exhibiting the corresponding behavior.

Table 5

Behavior	Pre-DE	3 Months Post-DE	6 Months Post-DE
some eye contact	0	2	5
toilet trained	1	2	3
some toilet training (not included above)	2	3	not available
some speech	2	3	6
formed bowel movement	1	2	6
hyperactive	5	3	1
plays with others	0	2	4
hand flapping	4	2	1

Furthermore, Table 6 outlines the responses that were reported after administration of digestive enzymes the autistic children of ages 5-12 (i.e., 11 of the 17 children listed in Table 4). Again, each numeric entry in Table 6 indicates the number of children (of the 11 children ages 5-12) exhibiting the corresponding behavior.

Table 6

Behavior	Pre-DE	3 Months Post-DE	6 Months Post-DE
some eye contact	8	6	8
toilet trained	3	6	6
some toilet training (not included above)	2	not available	4

	some speech	6	8	10
	formed bowel movement	2	7	10
	hyperactive	9	5	3
5	plays with others	3	5	8
	hand flapping	6	5	1

In summary, the results of the experiments described herein demonstrate that the fecal chymotrypsin level of an individual having one or more developmental disorders falling within the spectrum of PDD can be used as a marker to determine the benefit of administering secretin, other neuropeptides, peptides and/or digestive enzymes to the individual. Indeed, the above experiments indicate that the administration of secretin, other neuropeptides, peptides and/or digestive enzymes to children suffering from a disorder such as autism, ADD and ADHD, for example, and having sub-normal to pathologic levels of fecal chymotrypsin, will result in the amelioration of symptomatology of such disorders.

Although illustrative embodiments have been described herein with reference to the accompanying drawings, it is to be understood that the present invention is not limited to those precise embodiments, and that various other changes and modifications may be affected therein by one skilled in the art without departing from the scope or spirit of the invention. All such changes and modifications are intended to be included within the scope of the invention as defined by the appended claims.

WHAT IS CLAIMED IS:

1. A method for treating a disorder with secretin, the method comprising the step of administering to an individual having the disorder an effective amount of secretin based on the individual's chymotrypsin level to improve a symptom of the disorder.

5 2. The method of claim 1, comprising the steps of:
obtaining a sample of feces from the individual;
measuring a quantitative level of chymotrypsin present in the sample; and
comparing the measured quantitative level with at least one threshold chymotrypsin level to determine the efficacy of secretin administration to the individual.

10 3. The method of claim 2, wherein the at least one threshold chymotrypsin level is based on a level of chymotrypsin associated with at least one other individual of the same approximate age that does not have the disorder.

4. The method of claim 2, wherein the at least one threshold chymotrypsin level is approximately 8.4 U/gm.

15 5. The method of claim 2, wherein the at least one threshold chymotrypsin level is approximately 4.2 U/gm.

6. The method of claim 1, wherein the disorder comprises a disorder within a PDD (pervasive developmental disorder) spectrum.

20 7. The method of claim 1, wherein the disorder comprises autism.

8. A method for treating a disorder with digestive enzymes, the method comprising the step of administering to an individual having the disorder an effective amount of digestive enzymes based on the individual's chymotrypsin level to improve a symptom of the disorder.

9. The method of claim 8, comprising the steps of:

obtaining a sample of feces from the individual;
measuring a quantitative level of chymotrypsin present in the sample; and
comparing the measured quantitative level with at least one threshold chymotrypsin level to determine the efficacy of secretin administration to the individual.

5 10. The method of claim 9, wherein the at least one threshold chymotrypsin level is based on a level of chymotrypsin associated with at least one other individual of the same approximate age that does not have the disorder.

11. The method of claim 9, wherein the at least one threshold chymotrypsin level is approximately 8.4 U/gm.

10 12. The method of claim 9, wherein the at least one threshold chymotrypsin level is approximately 4.2 U/gm.

13. The method of claim 8, wherein the disorder comprises a disorder within a PDD (pervasive developmental disorder) spectrum.

14. The method of claim 8, wherein the disorder comprises autism.

15 15. The method of claim 8, wherein the disorder comprises one of ADD (Attention Deficit Disorder) and ADHD (Attention Deficit Hyperactivity Disorder) and both.

16. The method of claim 8, wherein the digestive enzymes comprise a pancreatic enzyme.

17. A method for treating an individual exhibiting a symptom of a PDD (pervasive
20 developmental disorder), the method comprising administering to the individual an effective amount of digestive enzymes to improve one or more symptoms of the disorder.

18. The method of claim 17, wherein the disorder comprises autism.

19. The method of claim 17, wherein the disorder comprises ADD (Attention Deficit Disorder), ADHD (Attention Deficit Hyperactivity Disorder) and both.

20. The method of claim 17, wherein the digestive enzymes comprise a pancreatic enzyme.

5

21. The method of claim 17, wherein the step of administering digestive enzymes comprises administering a quantitative level of digestive enzymes on a daily basis based at least on the age of the individual.

22. The method of claim 21, wherein the digestive enzymes are administered three
10 times per day.

23. A method for utilizing secretin to treat an individual having a disorder, the method comprising the steps of:

analyzing a stool sample of an individual to determine a quantitative level of a
compound present in the stool, wherein the quantitative level of the compound is indicative
15 of abnormal pancreatic function; and

administering to the individual an effective amount of secretin based on the
quantitative level of the compound so as to improve a symptom of the disorder.

24. The method of claim 23, wherein the compound comprises chymotrypsin.

20 25. The method of claim 23, wherein the disorder comprises a PDD (pervasive development disorder).

26. The method of claim 25, wherein the PDD comprises autism.

27. A method for utilizing digestive enzymes to treat an individual having a disorder, the method comprising the steps of:

analyzing a stool sample of an individual to determine a quantitative level of a compound present in the stool, wherein the quantitative level of the compound is indicative

5 of abnormal pancreatic function; and

administering to the individual an effective amount of digestive enzymes based on the quantitative level of the compound so as to improve a symptom of the disorder.

28. The method of claim 27, wherein the compound comprises chymotrypsin.

10 29. The method of claim 27, wherein the disorder comprises a PDD (pervasive development disorder).

30. The method of claim 29, wherein the PDD comprises autism.

Overall Net Change in CARS Sores




Fig. 1

%Percentage Change Post secretin




Fig. 2

Visual Response(Pre/Post) Secretin




Fig. 3

Verbal Skills(Pre/Post) Secretin




Fig. 4

Touch/Taste/Smell (Pre/Post) Secretin




Fig. 5

Object Use(Pre/Post) Secretin




Fig. 6

Listening (Pre/Post) Secretin




Fig. 7

Imitation (Pre/Post) Secretin




Fig. 8

Body Use (Pre/Post) Secretin




Fig. 9

Adaptation To Change (Pre/Post) Secretion




Fig. 10

Activity Level (Pre/Post) Secretin




Fig. 11

General Impression (pre/Post) Secretin




Fig. 12




Fig. 13




Fig. 14

ADD Fecal Chymotrypsin Levels




Fig 15

ADHD Fecal Chymotrypsin Levels




Fig 16

Ritalin Levels (mg) Pre/post secretin




Fig. 17

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 June 2001 (21.06.2001)

PCT

(10) International Publication Number
WO 01/43764 A3

- (51) International Patent Classification⁷: **A61K 38/22**, 38/54, C12Q 1/37, A61P 25/00
- (21) International Application Number: PCT/US00/34000
- (22) International Filing Date:
15 December 2000 (15.12.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
09/466,559 17 December 1999 (17.12.1999) US
09/707,395 7 November 2000 (07.11.2000) US
- (71) Applicant and
(72) Inventor: **FALLON, Joan, M.** [US/US]; 830 Pelhamdale Avenue, New Rochelle, NY 10801 (US).
- (74) Agents: **DEROSA, Frank, V.** et al.; F. Chau & Associates, LLP, 1900 Hempstead Turnpike, Suite 501, East Meadow, NY 11554 (US).
- (81) Designated States (*national*): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report
- (88) Date of publication of the international search report:
29 November 2001
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: METHODS FOR TREATING PERVASIVE DEVELOPMENT DISORDERS

(57) Abstract: Utilizing the chymotrypsin level of an individual as a measure of the success of secretin, other neuropeptides, and peptides or digestive enzyme in treating ADD, ADHD, Autism and other PDD related disorders. In one aspect, a method of determining the efficacy of secretin, other neuropeptides, peptides, or digestive enzymes for the treatment of an individual diagnosed with a pervasive development disorder (PDD) comprises obtaining a sample of feces from an individual, determining a quantitative level of chymotrypsin present in the sample, and correlating the quantitative level of chymotrypsin determined to be present in the sample with the PDD to determine the efficacy of treating the individual with secretin, other neuropeptides, peptides, or digestive enzyme administration.

WO 01/43764 A3

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/34000

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K38/22 A61K38/54 C12Q1/37 A61P25/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, MEDLINE, EMBASE, SCISEARCH, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 64059 A (REPLIGEN CORP) 16 December 1999 (1999-12-16)	1,6,7, 14,18,20
Y	page 3, line 6 - line 8 page 9, line 25 -page 10, line 2 example 1 ---	2-5, 23-26
X	WO 98 52593 A (UNIV MARYLAND) 26 November 1998 (1998-11-26)	1,6,7, 14,18,20
Y	page 7, line 2 - line 18 page 16, line 8 - line 10 page 23, line 17 - line 27 page 26, line 10 -page 28, line 8 --- -/--	2-5, 23-26

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * & * document member of the same patent family

Date of the actual completion of the international search

1 June 2001

Date of mailing of the international search report

29/06/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Pilling, S

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/34000

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5 250 418 A (KASPAR KLAUS P ET AL) 5 October 1993 (1993-10-05) column 1, line 13 - line 27 column 2, line 3 - line 9 ----	2-5, 9-12, 23-30
X	US 4 079 125 A (SIPOS TIBOR) 14 March 1978 (1978-03-14)	8,16
Y	abstract column 1, line 13 - line 20 column 5, line 20 - line 24 ----	9-12, 27-30
X	US 5 750 104 A (SIPOS TIBOR) 12 May 1998 (1998-05-12)	8,16
Y	abstract column 1, line 22 - line 26 column 6, line 11 - line 14 ----	9-12, 27-30
X	DE 43 32 985 A (SOMMER KONRAD PETER MARIA DR) 30 March 1995 (1995-03-30)	8,16
Y	abstract page 2, line 49 - line 51 ----	9-12, 27-30
X	US 5 985 891 A (ROWE JAMES BABER) 16 November 1999 (1999-11-16) column 2, line 36 - line 40 column 4, line 59 - column 5, line 19 column 8, line 7 - line 8 ----	8,13,15, 17,19, 21,22
P,X	WO 00 09142 A (MILKHAUS LAB INC) 24 February 2000 (2000-02-24) examples 1-8 -----	1,6,7

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/34000

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9964059 A	16-12-1999	US 6197746 B AU 4432299 A EP 1085901 A	06-03-2001 30-12-1999 28-03-2001
WO 9852593 A	26-11-1998	AU 7688598 A EP 1019072 A US 6020310 A	11-12-1998 19-07-2000 01-02-2000
US 5250418 A	05-10-1993	DE 3139719 A AT 12521 T AU 534001 B AU 8835082 A CA 1191772 A DD 203777 A DE 3262892 D DK 434082 A, B, EP 0076506 A ES 516124 D ES 8306389 A HU 187416 B IE 53472 B JP 1312229 C JP 58111699 A JP 60036758 B SU 1367866 A	21-04-1983 15-04-1985 22-12-1983 05-05-1983 13-08-1985 02-11-1983 09-05-1985 07-04-1983 13-04-1983 01-06-1983 16-08-1983 28-01-1986 23-11-1988 11-04-1986 02-07-1983 22-08-1985 15-01-1988
US 4079125 A	14-03-1978	AU 504584 B AU 1475576 A AU 516072 B AU 2968077 A BE 842822 A DE 2626109 A DK 256776 A, B, FI 761645 A FR 2313916 A GB 1509866 A IE 43601 B IN 144157 A JP 52003819 A NL 7606288 A NO 761981 A SE 7606470 A	18-10-1979 15-12-1977 14-05-1981 26-04-1979 10-12-1976 30-12-1976 11-12-1976 11-12-1976 07-01-1977 04-05-1978 08-04-1981 01-04-1978 12-01-1977 14-12-1976 13-12-1976 11-12-1976
US 5750104 A	12-05-1998	NONE	
DE 4332985 A	30-03-1995	NONE	
US 5985891 A	16-11-1999	AU 698600 B AU 4324596 A WO 9620709 A CA 2208986 A EP 0800394 A	05-11-1998 24-07-1996 11-07-1996 11-07-1996 15-10-1997
WO 0009142 A	24-02-2000	US 6020314 A AU 4985499 A	01-02-2000 06-03-2000